$5.275 billion for NIH is a healthy chunk of change—but read the fine print

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

This story is part of The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology. Our full coverage of SARS-CoV2 is available here.

A House subcommittee July 7 marked up a spending bill that proposes a $5.275 billion increase for NIH.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
Paul Goldberg
Editor & Publisher

Login